Related Experiment Video
Updated: Jun 2, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
Functional relevance of biased signaling at the angiotensin II type 1 receptor
1Department of Pharmaceutical Sciences, Jefferson School of Pharmacy, Thomas Jefferson University, Philadelphia, PA 1917, USA. douglas.tilley@jefferson.edu
Insights
Biased Angiotensin II type 1 receptor antagonists (AT1R) offer improved cardiovascular performance by selectively activating G protein-independent pathways. These novel ligands may surpass conventional ARBs in treating heart failure and hypertension.
Area of Science:
- Cardiovascular Pharmacology
- Molecular Signaling
- Drug Discovery
Background:
- Angiotensin II type 1 receptor blockers (ARBs) are standard treatments for cardiovascular diseases like hypertension and heart failure.
- Their efficacy stems from inhibiting Gα(q) protein signaling via the AT1 receptor.
- However, novel AT1R ligands demonstrate potential for enhanced cardiovascular benefits.
Purpose of the Study:
- To review recent findings on biased Angiotensin II type 1 receptor ligands.
- To explore the role of G protein-independent signaling in cardiovascular outcomes.
- To discuss the clinical potential of β-arrestin-biased AT1R ligands.
Main Methods:
- Literature review of recent studies on AT1R signaling.
- Analysis of biased AT1R ligand mechanisms.
- Discussion of preclinical and clinical implications.
Main Results:
- Identification of AT1R ligands that selectively inhibit Gα(q) signaling while activating β-arrestin pathways.
- Demonstration that these biased ligands may offer superior cardiovascular protection compared to conventional ARBs.
- Characterization of biased signaling as a distinct mode of AT1R modulation.
Conclusions:
- Biased AT1R ligands represent a promising therapeutic strategy for cardiovascular disorders.
- Targeting AT1R-β-arrestin signaling may lead to improved cardiovascular performance.
- Further research into biased ligands could redefine cardiovascular treatment paradigms.
Abstract:
Angiotensin II type 1 receptor antagonists (AT1R blockers, or ARBs) are used commonly in the treatment of cardiovascular disorders such as heart failure and hypertension. Their clinical success arises from their ability to prevent deleterious Gα(q) protein activation downstream of AT1R, which leads to a decrease in morbidity and mortality. Recent studies have identified AT1R ligands that concurrently inhibit Gα(q) protein-dependent signaling and activate Gα(q) protein-independent/β-arrestin-dependent signaling downstream of AT1R, events that may actually improve cardiovascular performance more than conventional ARBs. The ability of such ligands to induce intracellular signaling events in an AT1R-β-arrestin-dependent manner while preventing AT1R-Gα(q) protein activity defines them as biased AT1R ligands. This mini-review will highlight recent studies that have defined biased signaling at the AT1R and discuss the possible clinical relevance of β-arrestin-biased AT1R ligands in the cardiovascular system.
More Related Videos
09:51Live Cell Imaging and 3D Analysis of Angiotensin Receptor Type 1a Trafficking in Transfected Human Embryonic Kidney Cells Using Confocal Microscopy
Published on: March 27, 2017
07:21Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
Published on: September 28, 2015
Related Concept Videos
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Action of β1 Blockers
Adrenergic Receptors: ɑ Subtype
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Receptors: β Subtype
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Antihypertensive Drugs: Direct Renin Inhibitors